Bristol-Myers Squibb-Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today

Group 1: Stock Performance - Bristol Myers Squibb (BMY) stock closed at $53.78, showing a +1.34% change from the previous day's closing price, but lagged behind the S&P 500's daily gain of 9.52% [1] - The stock has decreased by 13.72% over the past month, which is worse than the Medical sector's loss of 14.16% and the S&P 500's loss of 13.47% [1] Group 2: Upcoming Earnings - The earnings report for Bristol Myers Squibb is anticipated on April 24, 2025, with expected earnings of$ 1.55 per share, reflecting a year-over-year growth of 135.23% [2] - Revenue is projected to be $10.69 billion, indicating a 9.94% decline from the same quarter last year [2] Group 3: Full Year Estimates - For the full year, earnings are estimated at$ 6.75 per share, representing a +486.96% change from the previous year, while revenue is projected at $45.59 billion, showing a -5.6% change [3] Group 4: Analyst Estimates - Recent changes in analyst estimates for Bristol Myers Squibb suggest a positive outlook on the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which reflects these estimate changes, indicates a current rank of 3 (Hold) for Bristol Myers Squibb [6] Group 5: Valuation Metrics - Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.86, which is below the industry average Forward P/E of 15.86 [7] - The company has a PEG ratio of 1.97, compared to the industry average PEG ratio of 1.31, indicating a relatively higher valuation based on anticipated earnings growth [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [8][9]